Aeon Biopharma Inc (AEON) Stock Price, Quote & News

Company Profile

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceu...

Industry: Biotechnology

Sector: Healthcare

Phone: 949 354 6499

Website: www.aeonbiopharma.com

Address:

5 Park Plaza, Suite 1750, Irvine, United States

HalEugene Nov. 14 at 7:58 PM

$AEON https://www.stocktitan.net/news/AEON/aeon-biopharma-reports-third-quarter-2025-results-including-positive-3y9d8yr742y1.html For those who are interested. It’s great news for the long term!

0 · Reply

JayM13 Nov. 14 at 5:27 PM

$AEON

0 · Reply

Mandi63 Nov. 14 at 2:29 PM

$AEON After reading yesterdays filings and news release…impressed with our new CEO ROB BANCROFT..

0 · Reply

wavy_ty Nov. 13 at 9:31 PM

$AEON This could either crash or explode. We’ll find out soon

1 · Reply

Mandi63 Nov. 13 at 9:26 PM

$AEON BULLISH..

0 · Reply

Paffff Nov. 13 at 8:33 PM

$AEON

0 · Reply

Otcgoblin Nov. 13 at 6:30 PM

$AEON going to .6

1 · Reply

Mandi63 Nov. 13 at 5:27 PM

$AEON $AEON Closed at $1.40 three weeks ago….super low float 11.4 million… BROAD FDA APPROVAL NOVEMBER 19TH PRICE TARGET $8.00 2025 $15.00 2026 $ATCH $DJT $KALA $OSCR

0 · Reply

BlondTaken Nov. 13 at 5:06 PM

$AEON Should be getting noticed now that 1.04 broke. bye for now...

0 · Reply

isaacwilliams33 Nov. 13 at 4:40 PM

$AEON small volume candle

0 · Reply

AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth

Nov 13, 2025, 8:30 AM EST - 1 day ago

AEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible Notes

Oct 1, 2025, 8:00 AM EDT - 6 weeks ago

AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19

Aug 12, 2025, 4:05 PM EDT - 3 months ago

AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update

May 23, 2025, 4:05 PM EDT - 6 months ago

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

May 19, 2025, 4:05 PM EDT - 6 months ago

AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025

May 14, 2025, 4:05 PM EDT - 6 months ago

AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 25, 2025, 4:05 PM EDT - 7 months ago

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Apr 21, 2025, 4:05 PM EDT - 7 months ago

AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer

Mar 27, 2025, 4:05 PM EDT - 8 months ago

AEON Biopharma Announces CEO Transition

Mar 24, 2025, 4:05 PM EDT - 8 months ago

AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 4, 2025, 8:00 AM EST - 9 months ago

AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference

Feb 24, 2025, 2:00 PM EST - 9 months ago

AEON Biopharma, Inc. Announces Reverse Stock Split

Feb 7, 2025, 4:05 PM EST - 10 months ago

AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Jan 7, 2025, 9:37 AM EST - 11 months ago

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

Jan 3, 2025, 8:02 PM EST - 11 months ago

AEON Biopharma, Inc. Announces Launch of Proposed Public Offering

Nov 13, 2024, 4:05 PM EST - 1 year ago

AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Aug 19, 2024, 4:05 PM EDT - 1 year ago

AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 12, 2024, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

May 29, 2024, 8:00 AM EDT - 1 year ago

AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan

May 14, 2024, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports First Quarter 2024 Financial Results

May 9, 2024, 8:00 AM EDT - 1 year ago

AEON Biopharma Provides Update on Development Pipeline

May 3, 2024, 7:00 AM EDT - 1 year ago

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

Mar 30, 2024, 10:53 PM EDT - 1 year ago

CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants

Mar 29, 2024, 4:15 PM EDT - 1 year ago

AEON Biopharma Announces Redemption of Public Warrants

Mar 29, 2024, 3:45 PM EDT - 1 year ago

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 19, 2024, 4:30 PM EDT - 1 year ago

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

Mar 19, 2024, 4:29 PM EDT - 1 year ago

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

Jan 18, 2024, 4:05 PM EST - 1 year ago

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

Dec 12, 2023, 8:00 AM EST - 2 years ago

AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine

Nov 13, 2023, 8:15 AM EST - 2 years ago

AEON Biopharma Reports Third Quarter 2023 Financial Results

Oct 19, 2023, 4:05 PM EDT - 2 years ago

AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine

Aug 29, 2023, 8:00 AM EDT - 2 years ago

AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®

Aug 24, 2023, 8:00 AM EDT - 2 years ago

AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache

Aug 16, 2023, 7:00 AM EDT - 2 years ago

Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma

Jul 24, 2023, 7:00 AM EDT - 2 years ago

AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update

HalEugene Nov. 14 at 7:58 PM

$AEON https://www.stocktitan.net/news/AEON/aeon-biopharma-reports-third-quarter-2025-results-including-positive-3y9d8yr742y1.html For those who are interested. It’s great news for the long term!

0 · Reply

JayM13 Nov. 14 at 5:27 PM

$AEON

0 · Reply

Mandi63 Nov. 14 at 2:29 PM

$AEON After reading yesterdays filings and news release…impressed with our new CEO ROB BANCROFT..

0 · Reply

wavy_ty Nov. 13 at 9:31 PM

$AEON This could either crash or explode. We’ll find out soon

1 · Reply

Mandi63 Nov. 13 at 9:26 PM

$AEON BULLISH..

0 · Reply

Paffff Nov. 13 at 8:33 PM

$AEON

0 · Reply

Otcgoblin Nov. 13 at 6:30 PM

$AEON going to .6

1 · Reply

Mandi63 Nov. 13 at 5:27 PM

$AEON $AEON Closed at $1.40 three weeks ago….super low float 11.4 million… BROAD FDA APPROVAL NOVEMBER 19TH PRICE TARGET $8.00 2025 $15.00 2026 $ATCH $DJT $KALA $OSCR

0 · Reply

BlondTaken Nov. 13 at 5:06 PM

$AEON Should be getting noticed now that 1.04 broke. bye for now...

0 · Reply

isaacwilliams33 Nov. 13 at 4:40 PM

$AEON small volume candle

0 · Reply

Mandi63 Nov. 13 at 4:22 PM

$AEON $AEON PRICE TARGET $8.20 for 2025 …. 15.00 for 2026 Broad FDA approval November 19th $FEMY $OPEN $EOLS $SANA

0 · Reply

BlondTaken Nov. 13 at 3:43 PM

$AEON very nice, once 1.04 breaks, we should have a nice run into tomorrows close at least. bye for now...

0 · Reply

BlondTaken Nov. 13 at 2:29 PM

$AEON Im liking this more I look into it, Botox, is a massive business, and this has a major catalyst coming for it, also they just got the dilution out the way today, and eliminated the debt by it, so they are a very good candidate to be either bought out, or merge with a bigger company once cleared fully to use, Im in today. bye for now...

0 · Reply

BlondTaken Nov. 13 at 2:19 PM

$AEON saw this cross my feed this morning, so we get the price the big boys get here. bye for now... https://www.sec.gov/ix?doc=/Archives/edgar/data/0001837607/000183760725000072/aeon-20251112x8k.htm

0 · Reply

Stock_Monster16 Nov. 13 at 1:45 PM

$AEON Not liking the lack of volume on news

0 · Reply

DaBullRunner Nov. 13 at 1:45 PM

$TNMG the team is banking 💰💰💰 SDA just waiting for the news to come out and it will go NUCKEAR I’m even willing to put some of my TESLA and COIN profits into SDA👇💰💰💰 $NVVE $AEON $GREE $WXM watching

0 · Reply

stgtrader1990 Nov. 13 at 1:42 PM

$AEON getting strong news, "Announces Biosimilarity Results Demonstrating Identical Amina Acid Sequence And Similar Functional Analysis Data Between ABP-450 And BOTOX" (Benzinga News Desk). Very low volume but also a low float (11.610M). These low floats tend to squeeze big under the right conditions. Needs more volume to pour in though.

0 · Reply

Mandi63 Nov. 11 at 8:17 PM

$AEON $2.00-5.00 next week…

0 · Reply

Mandi63 Nov. 11 at 2:15 PM

$AEON Premarket was $1.07..

0 · Reply

HalEugene Nov. 7 at 11:50 PM

$AEON In case anyone wants information from AEON, you can register with them@ https://investors.aeonbiopharma.com I have also emailed them to ask whether they will be having an earnings call this month. Any information I receive, I will share/post.

2 · Reply

HalEugene Nov. 7 at 9:50 PM

$AEON Hi all, Earnings data/release moved to 11/21 after FDA meeting on 11/19. Have a good weekend!

2 · Reply

JayM13 Nov. 7 at 4:58 PM

$AEON another dip please…

0 · Reply

Market Cap	10.95M
Revenue (ttm)	0.00
Net Income (ttm)	42.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	150,000
Avg Vol	255,076
Day's Range	N/A - N/A
Shares Out	11.64M
Stochastic %K	23%
Beta	0.75
Analysts	Strong Sell
Price Target	$7.20